299P: First-line (1L) durvalumab (D) + platinum-etoposide (EP) in extensive-stage SCLC (ES-SCLC): Final results and exploratory biomarker analyses from LUMINANCE
2025 · Journal of Thoracic Oncology · 0 citations
https://doi.org/10.1016/s1556-0864(25)00491-5